Show simple item record

dc.contributor.authorHeskamp, S
dc.contributor.authorHeijmen, L
dc.contributor.authorGerrits, D
dc.contributor.authorMolkenboer-Kuenen, JDM
dc.contributor.authorTer Voert, EGW
dc.contributor.authorHeinzmann, K
dc.contributor.authorHoness, DJ
dc.contributor.authorSmith, D-M
dc.contributor.authorGriffiths, JR
dc.contributor.authorDoblas, S
dc.contributor.authorSinkus, R
dc.contributor.authorLaverman, P
dc.contributor.authorOyen, WJG
dc.contributor.authorHeerschap, A
dc.contributor.authorBoerman, OC
dc.date.accessioned2017-07-21T10:51:38Z
dc.date.issued2017-08
dc.identifier.citationMolecular imaging and biology, 2017, 19 (4), pp. 540 - 549
dc.identifier.issn1536-1632
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/739
dc.identifier.eissn1860-2002
dc.identifier.doi10.1007/s11307-016-1021-2
dc.description.abstractPURPOSE:The aim of the study was to investigate the potential of diffusion-weighted magnetic resonance imaging (DW-MRI) and 3'-dexoy-3'-[18F]fluorothymidine ([18F]FLT) positron emission tomography (PET) as early biomarkers of treatment response of 5-fluorouracil (5-FU) in a syngeneic rat model of colorectal cancer liver metastases. PROCEDURES:Wag/Rij rats with intrahepatic syngeneic CC531 tumors were treated with 5-FU (15, 30, or 60 mg/kg in weekly intervals). Before treatment and at days 1, 3, 7, and 14 after treatment rats underwent DW-MRI and [18F]FLT PET. Tumors were analyzed immunohistochemically for Ki67, TK1, and ENT1 expression. RESULTS:5-FU inhibited the growth of CC531 tumors in a dose-dependent manner. Immunohistochemical analysis did not show significant changes in Ki67, TK1, and ENT1 expression. However, [18F]FLT SUVmean and SUVmax were significantly increased at days 4 and 7 after treatment with 5-FU (60 mg/kg) and returned to baseline at day 14 (SUVmax at days -1, 4, 7, and 14 was 1.1 ± 0.1, 2.3 ± 0.5, 2.3 ± 0.6, and 1.5 ± 0.4, respectively). No changes in [18F]FLT uptake were observed in the nontreated animals. Furthermore, the apparent diffusion coefficient (ADCmean) did not change in 5-FU-treated rats compared to untreated rats. CONCLUSION:This study suggests that 5-FU treatment induces a flare in [18F]FLT uptake of responsive CC531 tumors in the liver, while the ADCmean did not change significantly. Future studies in larger groups are warranted to further investigate whether [18F]FLT PET can discriminate between disease progression and treatment response.
dc.formatPrint
dc.format.extent540 - 549
dc.languageeng
dc.language.isoeng
dc.relation.replacesinternal/205
dc.relation.replaceshttps://repository.icr.ac.uk/handle/internal/205
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectCell Line, Tumor
dc.subjectAnimals
dc.subjectRats
dc.subjectColorectal Neoplasms
dc.subjectLiver Neoplasms
dc.subjectDisease Models, Animal
dc.subjectFluorouracil
dc.subjectDideoxynucleosides
dc.subjectPositron-Emission Tomography
dc.subjectTomography, Emission-Computed, Single-Photon
dc.subjectTomography, X-Ray Computed
dc.subjectDiffusion Magnetic Resonance Imaging
dc.subjectTreatment Outcome
dc.subjectImmunohistochemistry
dc.subjectCell Death
dc.subjectCell Proliferation
dc.titleResponse Monitoring with [18F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases.
dc.typeJournal Article
dcterms.dateAccepted2017-07-09
rioxxterms.versionofrecord10.1007/s11307-016-1021-2
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfMolecular imaging and biology
pubs.issue4
pubs.merge-frominternal/205
pubs.merge-fromhttps://repository.icr.ac.uk/handle/internal/205
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.publication-statusPublished
pubs.volume19
pubs.embargo.termsNot known
icr.researchteamTranslational Molecular Imagingen_US
dc.contributor.icrauthorHeinzmann, Kathrinen
dc.contributor.icrauthorOyen, Willemen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0